Skip to main content

Long Term Safety Following GM T Cell Therapy

0
Pipeline Programs
1
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Regeneron
RegeneronTARRYTOWN, NY
1 program
Non-interventionalN/A3 trials
Active Trials
NCT06798298Recruiting50Est. Jun 2040
NCT05673967Completed62Est. Mar 2025
NCT05338892Completed595Est. Oct 2023

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
RegeneronNon-interventional
RegeneronNon-interventional
RegeneronNon-interventional

Clinical Trials (3)

Total enrollment: 707 patients across 3 trials

NCT06798298RegeneronNon-interventional

A Safety and Efficacy Long-Term Follow-up Study of Adult Participants Treated With Gene Modified T Cells

Start: Nov 2025Est. completion: Jun 204050 patients
N/ARecruiting
NCT05673967RegeneronNon-interventional

Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma

Start: Jan 2023Est. completion: Mar 202562 patients
N/ACompleted
NCT05338892RegeneronNon-interventional

Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Start: Jun 2022Est. completion: Oct 2023595 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 707 patients
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.